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tory potency) can be retrieved from libraries within the simulator. 
However, the information on each patient (ie, demography, physi-
ology, genetics, enzyme abundances and activity, level of plasma 
proteins, kidney function, various drugs taken and their dosage 
information) are also required. Some of these are not available rou-
tinely and hold the key to “Clinical Oriented” applications (eg, in 
iPad and so on).
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Developing a stanDarDiseD prescription 
chart to reDuce error
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Cardiff, United Kingdom
Summary: Unfamiliarity is an important contributor to error, includ-
ing medication errors, some of which result in adverse events. Paper-
based inpatient prescription charts differ in different hospitals, and 
medical trainees move around health care systems, so they may be 
unfamiliar with such charts initially.
Standards for the design of inpatient prescriptions charts have 
recently been agreed by the Academy of Medical Royal Colleges 
in the United Kingdom.1 In several studies, standardization of pre-
scribing documents has been associated with significantly reduced 
medication errors in adults in Australia,2 as well as in some aspects of 
pediatric medicine. The introduction of a single inpatient prescription 
chart in Wales in 20043 and its subsequent continuing development 
will be described. The training resources developed to support the 
chart will also be discussed.
Standardization of prescribing standards, of acceptable abbrevia-
tions, and standardized training in prescribing can also all contribute 
to a reduction in medication errors and associated adverse events, 
including when electronic rather than paper-based prescriptions are 
written.
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the inDiviDualisation of cancer therapy 
in organ Dysfunction
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Oncology, Johns Hopkins University, Baltimore, Maryland
Summary: Cancer patients with adequate hepatic or renal func-
tion are typically studied during drug development. The majority 
of anticancer agents are cleared by via hepatic or renal mechanisms. 
Therefore, dose adjustments would be anticipated in patients with 
organ dysfunction. However, when a drug is approved, dosing modi-
fication guidelines are often lacking for patients who have varying 
degrees of hepatic or renal dysfunction, especially moderate or severe 
dysfunction. In clinical practice, oncologists may start therapy with 
an empirically derived lower starting dose due to the perception that 
a patient with organ dysfunction would have poorer tolerability 
due to increased toxicity. The presentation will summarize: (1) A 
brief historical perspective of individualization of cancer therapy 
in organ dysfunction; (2) pathophysiology of organ dysfunction in 
cancer patients; (3) barriers to the conduct of clinical trials in this 
population; and (4) recent examples of dosing recommendations for 
anticancer agents.
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Summary: In addition to the increasing number of biological and 
biotechnological medicinal products available for different clinical 
indications, the development of gene- and cell-based products offer 
alternative approaches for the prevention and treatment of human 
diseases. An increasing number of gene therapy and somatic cell ther-
apy products are already in clinical development for the treatment 
of inherited diseases, cancer, diabetes, Parkinson’s disease, and other 
neurodegenerative disorders. As gene and cell therapy products are 
presented as having properties for treating or preventing diseases in 
human beings, or that they may be used in or administered to human 
beings with a view to restoring, correcting, or modifying physiologi-
cal functions by exerting principally a pharmacologic, immunologic, 
or metabolic action, they are considered biological medicinal prod-
ucts within the meaning of Annex I to Directive 2001/83/EC of the 
European Parliament and of the Council of 6 November 2001 on 
the Community code relating to medicinal products for human use.
Regulation (EC) 1394/2007 introduces additional provisions to 
those laid down in Directive 2001/83/EC and regulates advanced 
therapies that are intended to be placed on the market in the EU 
Member States and either prepared industrially or manufactured by 
a method involving an industrial process. However, ATMP “prepared 
on a non-routine basis according to specific quality standards, and 
used within the same Member State in a hospital under the exclu-
sive professional responsibility of a medical practitioner, in order to 
comply with an individual medical prescription for a custom-made 
product for an individual patient” are excluded. EU Member States 
are currently developing the rules to apply to these products to guar-
antee their quality and safety.
A review of gene therapy medicinal products that have applied 
for marketing authorization application through the European 
Medicines Agency will be presented.
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Summary: The athlete biological passport (ABP) is an individual and 
longitudinal monitoring of biomarkers potentially linked to doping. 
